NBIX - Neurocrine Biosciences, Inc.
IEX Last Trade
127.06
-1.370 -1.078%
Share volume: 1,236,878
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$128.43
-1.37
-1.07%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-01 | 2023-02-09 | 2023-05-03 | 2023-08-01 | 2023-10-31 | 2024-02-09 | 2024-05-01 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 2.143 B | 2.369 B | 2.360 B | 2.613 B | 2.848 B | 3.251 B | 3.472 B | 3.305 B | |
| Current Assets | 1.206 B | 1.454 B | 1.433 B | 1.497 B | 1.650 B | 1.607 B | 1.799 B | 1.670 B | |
| Inventories | 37.000 M | 35.100 M | 33.400 M | 31.700 M | 28.800 M | 38.300 M | 37.200 M | 42.500 M | |
| Other Current Assets | 67.900 M | 79.100 M | 113.200 M | 100.600 M | 108.200 M | 97.800 M | 100.500 M | 120.200 M | |
| Short Term Investments | 67.900 M | 79.100 M | 113.200 M | 100.600 M | 108.200 M | 97.800 M | 100.500 M | 120.200 M | |
| Total Receivables | 301.200 M | 350.000 M | 391.600 M | 387.600 M | 417.800 M | 439.300 M | 450.700 M | 468.200 M | |
| Current Cash | 799.400 M | 989.300 M | 894.600 M | 976.700 M | 1.095 B | 1.032 B | 1.211 B | 1.039 B | |
| Total Non-current Assets | 937.900 M | 915.200 M | 927.000 M | 1.117 B | 1.198 B | 1.644 B | 1.673 B | 1.635 B | |
| Property Plant Equipment | 60.900 M | 58.600 M | 62.800 M | 65.600 M | 68.800 M | 70.800 M | 75.300 M | 80.100 M | |
| Other Assets | 10.500 M | 25.000 M | 24.900 M | 35.900 M | 43.100 M | 49.600 M | 50.900 M | 57.800 M | |
| Intangible Assets | 0.000 | 37.200 M | 37.200 M | 36.900 M | 34.900 M | 35.500 M | 34.300 M | 33.500 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.143 B | 2.369 B | 2.360 B | 2.613 B | 2.848 B | 3.251 B | 3.472 B | 3.305 B | |
| Total liabilities | 598.800 M | 660.900 M | 675.300 M | 760.100 M | 846.200 M | 1.019 B | 1.086 B | 796.000 M | |
| Total current liabilities | 485.100 M | 537.700 M | 374.100 M | 582.500 M | 691.700 M | 654.800 M | 712.900 M | 398.700 M | |
| Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 17.100 M | 29.700 M | 41.300 M | 88.500 M | 68.600 M | 106.300 M | 120.500 M | 141.100 M | |
| Current long term debt | 169.200 M | 169.400 M | 0.000 | 169.700 M | 169.900 M | 170.100 M | 122.800 M | 0.000 | |
| Long term debt | 0.000 | 0.000 | 169.500 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 17.100 M | 29.700 M | 41.300 M | 88.500 M | 68.600 M | 106.300 M | 120.500 M | 141.100 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.545 B | 1.708 B | 1.685 B | 1.853 B | 2.002 B | 2.232 B | 2.386 B | 2.509 B | |
| Common stock | 95.800 M | 96.500 M | 97.100 M | 97.600 M | 97.900 M | 98.200 M | 99.800 M | 100.800 M | |
| Retained earnings | -495.800 M | -406.800 M | -483.400 M | -387.900 M | -304.800 M | -157.100 M | -113.700 M | -48.700 M |